Lumbrokinase from earthworm extract ameliorates second-hand smoke-induced cardiac fibrosis

Environmental Toxicology

Volumn 30, Issue 10, 2015, Pages 1216-1225

  Lai, Chao Hung ^a,b   Han, Chien Kuo ^c   Shibu, Marthandam Asokan ^a   Pai, Pei Ying ^d   Ho, Tsung Jung ^a,e   Day, Cecilia Hsuan ^f   Tsai, Fuu Jen ^a   Tsai, Chang Hai ^c   Yao, Chun Hsu ^a   Huang, Chih Yang ^a,c  

^a CHINA MEDICAL UNIVERSITY   (Taiwan)

^b TAICHUNG ARMED FORCES GENERAL HOSPITAL   (Taiwan)

^c ASIA UNIVERSITY   (Taiwan)

^d CHINA MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

^e CHINA MEDICAL UNIVERSITY BEIGANG HOSPITAL   (Taiwan)

^f MEIHO UNIVERSITY   (Taiwan)

Author keywords

Cardiac fibrosis; Dilong; Lumbrokinase; Second hand smoke

Indexed keywords

CARDIOLOGY; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYMES; PROTEINS; RATS; SMOKE; TOBACCO;

CARDIAC FIBROSIS; CARDIO-VASCULAR DISEASE; DILONG; EPITHELIAL-MESENCHYMAL TRANSITION; EXTRACELLULAR SIGNAL-REGULATED KINASE; LUMBROKINASE; MYOCARDIAL INFRACTION; SECOND HAND SMOKES;

HEART;

ALPHA TUBULIN; CARDIOVASCULAR AGENT; DILONG; EARTHWORM EXTRACT; FIBROBLAST GROWTH FACTOR 2; GELATINASE A; GELATINASE B; LUMBROKINASE; MATRIX METALLOPROTEINASE; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; MOLECULAR MARKER; PLASMIN; PROTECTIVE AGENT; PROTEIN BAD; TRANSCRIPTION FACTOR SP1; UNCLASSIFIED DRUG; UROKINASE; PASSIVE SMOKING; PROTEINASE;

ANIMAL EXPERIMENT; ARTICLE; CONGESTIVE CARDIOMYOPATHY; ELECTROPHORESIS; EPITHELIAL MESENCHYMAL TRANSITION; HEART INJURY; HEART LEFT VENTRICLE; HEART MUSCLE FIBROSIS; HEART PROTECTION; MITOCHONDRIAL PERMEABILITY; NONHUMAN; PASSIVE SMOKING; PRIORITY JOURNAL; RAT; TISSUE GROWTH; ADVERSE EFFECTS; ANIMAL; CARDIOMYOPATHY, DILATED; DRUG EFFECTS; ENZYMOLOGY; FIBROSIS; HEART; HEART MUSCLE; ISOLATION AND PURIFICATION; METABOLISM; OLIGOCHAETA; PATHOLOGY; SIGNAL TRANSDUCTION; SPRAGUE DAWLEY RAT;

NICOTIANA TABACUM; RATTUS;

ANIMALS; CARDIOMYOPATHY, DILATED; ENDOPEPTIDASES; FIBROSIS; HEART; MATRIX METALLOPROTEINASES; MITOGEN-ACTIVATED PROTEIN KINASE 1; MITOGEN-ACTIVATED PROTEIN KINASE 3; MYOCARDIUM; OLIGOCHAETA; RATS; RATS, SPRAGUE-DAWLEY; SIGNAL TRANSDUCTION; SP1 TRANSCRIPTION FACTOR; TOBACCO SMOKE POLLUTION;

EID: 84941183008     PISSN: 15204081     EISSN: 15227278     Source Type: Journal    
DOI: 10.1002/tox.21993     Document Type: Article

References (70)

1. Anversa P, Kajstura J, Olivetti G. 1996. Myocyte death in heart failure. Curr Opin Cardiol 11:245-251.
2. Anversa P, Nadal-Ginard B. 2002. Myocyte renewal and ventricular remodelling. Nature 415:240-243.
3. Balamurugan M, Parthasarathi K, Cooper EL, Ranganathan LS. 2007. Earthworm paste (Lampito mauritii, Kinberg) alters inflammatory, oxidative, haematological and serum biochemical indices of inflamed rat. Eur Rev Med Pharmacol Sci 11:77-90.
4. Baud FJ, Barriot P, Toffis V, Riou B, Vicaut E, Lecarpentier Y, Bourdon R, Astier A, Bismuth C. 1991. Elevated blood cyanide concentrations in victims of smoke inhalation. N Engl J Med 325:1761-1766.
5. Bradford MM. 1976. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 72:248-254.
6. Bronnum-Hansen H. 2000. Predicted effect of smoking cessation of tobacco-related mortality. Ugeskr Laeger 162:5772-5777.
7. Cho IH, Choi ES, Lim HG, Lee HH. 2004. Purification and characterization of six fibrinolytic serine-proteases from earthworm Lumbricus rubellus. J Biochem Mol Biol 37:199-205.
8. Cooper EL, Balamurugan M, Huang C-Y, Tsao CR, Heredia J, Tommaseo-Ponzetta M, Paoletti MG. 2012. Earthworms Dilong: Ancient, Inexpensive, Noncontroversial Models May Help Clarify Approaches to Integrated Medicine Emphasizing Neuroimmune Systems. Evid Based Complement Alternat Med 11.
9. Cushing MC, Mariner PD, Liao JT, Sims EA, Anseth KS. 2008. Fibroblast growth factor represses Smad-mediated myofibroblast activation in aortic valvular interstitial cells. Faseb J 22:1769-1777.
10. Eghbali M. 1992. Cardiac fibroblasts: Function, regulation of gene expression, and phenotypic modulation. Basic Res Cardiol 87 (Suppl 2):183-189.
11. Fernandes-Alnemri T, Litwack G, Alnemri ES. 1994. CPP32, a novel human apoptotic protein with homology to Caenorhabditis elegans cell death protein Ced-3 and mammalian interleukin-1 beta-converting enzyme. J Biol Chem 269:30761-30764.
12. Frantz S, Hu K, Adamek A, Wolf J, Sallam A, Maier SK, Lonning S, Ling H, Ertl G, Bauersachs J. 2008. Transforming growth factor beta inhibition increases mortality and left ventricular dilatation after myocardial infarction. Basic Res Cardiol 103:485-492.
13. Gaertner R, Jacob MP, Prunier F, Angles-Cano E, Mercadier JJ, Michel JB. 2005. The plasminogen-MMP system is more activated in the scar than in viable myocardium 3 months post-MI in the rat. J Mol Cell Cardiol 38:193-204.
14. Galiuto L, Lotrionte M, Crea F, Anselmi A, Biondi-Zoccai GGL, De Giorgio F, Baldi A, Baldi F, Possati G, Gaudino M, Vetrovec GW, Abbate A. 2006. Impaired coronary and myocardial flow in severe aortic stenosis is associated with increased apoptosis: A transthoracic Doppler and myocardial contrast echocardiography study. Heart 92:208-212.
15. Ghosh AK, Bradham WS, Gleaves LA, De Taeye B, Murphy SB, Covington JW, Vaughan DE. 2010. Genetic deficiency of plasminogen activator inhibitor-1 promotes cardiac fibrosis in aged mice: Involvement of constitutive transforming growth factor-beta signaling and endothelial-to-mesenchymal transition. Circulation 122:1200-1209.
16. Glantz SA, Parmley WW. 1991. Passive smoking and heart disease. Epidemiology, physiology, and biochemistry. Circulation 83:1-12.
17. GunjaSmith Z, Morales AR, Romanelli R, Woessner JF. 1996. Remodeling of human myocardial collagen in idiopathic dilated cardiomyopathy-Role of metalloproteinases and pyridinoline cross-links. Am J Pathol 148:1639-1648.
18. Haunstetter A, Izumo S. 1998. Apoptosis-Basic mechanisms and implications for cardiovascular disease. Circ Res 82:1111-1129.
19. Hawkridge AM, Heublein DM, Bergen HR III, Cataliotti A, Burnett JC Jr, Muddiman DC. 2005. Quantitative mass spectral evidence for the absence of circulating brain natriuretic peptide (BNP-32) in severe human heart failure. Proc Natl Acad Sci USA 102:17442-17447.
20. He J, Vupputuri S, Allen K, Prerost MR, Hughes J, Whelton PK. 1999. Passive smoking and the risk of coronary heart disease-A meta-analysis of epidemiologic studies. N Engl J Med 340:920-926.
21. Health USNIo. 1984. Laboratory animal welfare; proposed U.S. government principles for the utilization and care of vertebrate animals used in testing, research and training. Fed Regist 49:29350-29351.
22. Heymans S, Luttun A, Nuyens D, Theilmeier G, Creemers E, Moons L, Dyspersin GD, Cleutjens JP, Shipley M, Angellilo A, Levi M, Nube O, Baker A, Keshet E, Lupu F, Herber JM, Smits JF, Shapiro SD, Baes M, Borgers M, Collen D, Daemen MJ, Carmeliet P. 1999. Inhibition of plasminogen activators or matrix metalloproteinases prevents cardiac rupture but impairs therapeutic angiogenesis and causes cardiac failure. Nat Med 5:1135-1142.
23. Heymans S, Lupu F, Terclavers S, Vanwetswinkel B, Herbert JM, Baker A, Collen D, Carmeliet P, Moons L. 2005. Loss or inhibition of uPA or MMP-9 attenuates LV remodeling and dysfunction after acute pressure overload in mice. Am J Pathol 166:15-25.
24. Hole DJ, Gillis CR, Chopra C, Hawthorne VM. 1989. Passive smoking and cardiorespiratory health in a general population in the west of Scotland. BMJ 299:423-427.
25. Holmes A, Abraham DJ, Chen YJ, Denton C, Xu SW, Black CM, Leask A. 2003. Constitutive connective tissue growth factor expression in scleroderma fibroblasts is dependent on Sp1. J Biol Chem 278:41728-41733.
26. Huang C-Y, Kuo W-W, Liao H-E, Lin Y-M, Kuo C-H, Tsai F-J, Tsai C-H, Chen J-L, Lin J-Y. 2013. Lumbrokinase attenuates side-stream-smoke-induced apoptosis and autophagy in young hamster hippocampus: Correlated with eNOS induction and NFκB/iNOS/COX-2 signaling suppression. Chem Res Toxicol 26:654-661.
27. Huang C-Y, Lee S-D. 2012. Possible pathophysiology of heart failure in obesity: Cardiac apoptosis. BioMedicine 2:36-40.
28. Hwang JM, Wu CH, Kuo WW, Jong GP, Lai CH, Tsai CH, Tsai FJ, Chang MH, Wu JP, Huang CY. 2012. Pro-inflammation and pro-fibrosis factors were highly induction in heart tissues of carotid arteries balloon-injured animal model. Cell Biochem Funct 30:390-394.
29. Ikeuchi M, Tsutsui H, Shiomi T, Matsusaka H, Matsushima S, Wen J, Kubota T, Takeshita A. 2004. Inhibition of TGF-beta signaling exacerbates early cardiac dysfunction but prevents late remodeling after infarction. Cardiovasc Res 64:526-535.
30. Jao C-L, Huang S-L, Hsu K-C. 2012. Angiotensin I-converting enzyme inhibitory peptides: Inhibition mode, bioavailability, and antihypertensive effects. BioMedicine 2:130-136.
31. Jian B, Narula N, Li QY, Mohler ER, Levy RJ. 2003. Progression of aortic valve stenosis: TGF-beta 1 is present in calcified aortic valve cusps and promotes aortic valve interstitial cell calcification via apoptosis. Ann Thorac Surg 75:457-465.
32. Jousilahti P, Patja K, Salomaa V. 2002. Environmental tobacco smoke and the risk of cardiovascular disease. Scand J Work Environ Health 28 (Suppl 2):41-51.
33. Kaden JJ, Dempfle CE, Grobholz R, Fischer CS, Vocke DC, Kilic R, Sarikoc A, Pinol R, Hagl S, Lang S, Brueckmann M, Borggrefe M. 2005. Inflammatory regulation of extracellular matrix remodeling in calcific aortic valve stenosis. Cardiovasc Pathol 14:80-87.
34. Kapur NK. 2011. Transforming growth factor-beta: Governing the transition from inflammation to fibrosis in heart failure with preserved left ventricular function. Circ Heart Fail 4:5-7.
35. Kasim M, Kiat AA, Rohman MS, Hanifah Y, Kiat H. 2009. Improved myocardial perfusion in stable angina pectoris by oral lumbrokinase: A pilot study. J Altern Complement Med 15:539-544.
36. Kim S, Iwao H. 2000. Molecular and cellular mechanisms of angiotensin II-mediated cardiovascular and renal diseases. Pharmacol Rev 52:11-34.
37. Koesters R, Kaissling B, Lehir M, Picard N, Theilig F, Gebhardt R, Glick AB, Hahnel B, Hosser H, Grone HJ, Kriz W. 2010. Tubular overexpression of transforming growth factor-beta1 induces autophagy and fibrosis but not mesenchymal transition of renal epithelial cells. Am J Pathol 177:632-643.
38. Kuo WW, Wu CH, Lee SD, Lin JA, Chu CY, Hwang JM, Ueng KC, Chang MH, Yeh YL, Wang CJ, Liu JY, Huang CY. 2005. Second-hand smoke-induced cardiac fibrosis is related to the Fas death receptor apoptotic pathway without mitochondria-dependent pathway involvement in rats. Environ Health Perspect 113:1349-1353.
39. La Vecchia C, D'Avanzo B, Franzosi MG, Tognoni G. 1993. Passive smoking and the risk of acute myocardial infarction GISSI-EFRIM investigations. Lancet 341:505-506.
40. Law MR, Morris JK, Wald NJ. 1997. Environmental tobacco smoke exposure and ischaemic heart disease: An evaluation of the evidence. BMJ 315:973-980.
41. Leivonen SK, Hakkinen L, Liu D, Kahari VM. 2005. Smad3 and extracellular signal-regulated kinase 1/2 coordinately mediate transforming growth factor-beta-induced expression of connective tissue growth factor in human fibroblasts. J Invest Dermatol 124:1162-1169.
42. Lijnen HR. 2001. Plasmin and matrix metalloproteinases in vascular remodeling. Thromb Haemost 86:324-333.
43. Mann DL, Spinale FG. 1998. Activation of matrix metalloproteinases in the failing human heart-Breaking the tie that binds. Circulation 98:1699-1702.
44. Massague J. 1998. TGF-beta signal transduction. Annu Rev Biochem 67:753-791.
45. Meyer A, Wang W, Qu J, Croft L, Degen JL, Coller BS, Ahamed J. 2012. Platelet TGF-beta1 contributions to plasma TGF-beta1, cardiac fibrosis, and systolic dysfunction in a mouse model of pressure overload. Blood 119:1064-1074.
46. Miles LA, Parmer RJ. 2010. PAI-1: Cardiac friend or foe? Blood 115:1862-1863.
47. Moriwaki H, Stempien-Otero A, Kremen M, Cozen AE, Dichek DA. 2004. Overexpression of urokinase by macrophages or deficiency of plasminogen activator inhibitor type 1 causes cardiac fibrosis in mice. Circ Res 95:637-644.
48. Narula J, Haider N, Virmani R, DiSalvo TG, Kolodgie FD, Hajjar RJ, Schmidt U, Semigran MJ, Dec GW, Khaw BA. 1996. Apoptosis in myocytes in end-stage heart failure. N Engl J Med 335:1182-1189.
49. Okada H, Takemura G, Kosai K, Li Y, Takahashi T, Esaki M, Yuge K, Miyata S, Maruyama R, Mikami A, Minatoguchi S, Fujiwara T, Fujiwara H. 2005. Postinfarction gene therapy against transforming growth factor-beta signal modulates infarct tissue dynamics and attenuates left ventricular remodeling and heart failure. Circulation 111:2430-2437.
50. Peterson JT, Hallak H, Johnson L, Li H, O'Brien PM, Sliskovic DR, Bocan TM, Coker ML, Etoh T, Spinale FG. 2001. Matrix metalloproteinase inhibition attenuates left ventricular remodeling and dysfunction in a rat model of progressive heart failure. Circulation 103:2303-2309.
51. Porter AG, Janicke RU. 1999. Emerging roles of caspase-3 in apoptosis. Cell Death Differ 6:99-104.
52. Riches K, Morley ME, Turner NA, O'Regan DJ, Ball SG, Peers C, Porter KE. 2009. Chronic hypoxia inhibits MMP-2 activation and cellular invasion in human cardiac myofibroblasts. J Mol Cell Cardiol 47:391-399.
53. Ruiz-Ortega M, Rodriguez-Vita J, Sanchez-Lopez E, Carvajal G, Egido J. 2007. TGF-beta signaling in vascular fibrosis. Cardiovasc Res 74:196-206.
54. Serini G, Bochaton-Piallat ML, Ropraz P, Geinoz A, Borsi L, Zardi L, Gabbiani G. 1998. The fibronectin domain ED-A is crucial for myofibroblastic phenotype induction by transforming growth factor-beta 1. J Cell Biol 142:873-881.
55. Steenland K, Thun M, Lally C, Heath C Jr. 1996. Environmental tobacco smoke and coronary heart disease in the American Cancer Society CPS-II cohort. Circulation 94:622-628.
56. Stempien-Otero A, Plawman A, Meznarich J, Dyamenahalli T, Otsuka G, Dichek DA. 2006. Mechanisms of cardiac fibrosis induced by urokinase plasminogen activator. J Biol Chem 281:15345-15351.
57. Sun YG, Zhang Y, Yan M, Wu YB, Zheng XX. 2009. B-type natriuretic peptide-induced cardioprotection against reperfusion is associated with attenuation of mitochondrial permeability transition. Biol Pharma Bull 32:1545-1551.
58. Tamaoki M, Imanaka-Yoshida K, Yokoyama K, Nishioka T, Inada H, Hiroe M, Sakakura T, Yoshida T. 2005. Tenascin-C regulates recruitment of myofibroblasts during tissue repair after myocardial injury. Am J Pathol 167:71-80.
59. Teo KK, Ounpuu S, Hawken S, Pandey MR, Valentin V, Hunt D, Diaz R, Rashed W, Freeman R, Jiang L, Zhang X, Yusuf S. 2006. Tobacco use and risk of myocardial infarction in 52 countries in the INTERHEART study: A case-control study. Lancet 368:647-658.
60. Topol EJ, Califf RM. 2007. Textbook of Cardiovascular Medicine. Philadelphia: Lippincott Williams & Wilkins. xxix, 1628 p.
61. Tunstall-Pedoe H, Brown CA, Woodward M, Tavendale R. 1995. Passive smoking by self report and serum cotinine and the prevalence of respiratory and coronary heart disease in the Scottish heart health study. J Epidemiol Community Health 49:139-143.
62. Tyagi SC. 1997. Proteinases and myocardial extracellular matrix turnover. Mol Cell Biochem 168:1-12.
63. Tyagi SC, Kumar S, Reddy SR, Reddy HK, Voelker DJ, Janicki JS. 1996. Extracellular matrix regulation of metalloproteinase and antiproteinase in human heart fibroblast cells. J Cell Physiol 167:137-147.
64. Walker GA, Masters KS, Shah DN, Anseth KS, Leinwand LA. 2004. Valvular myofibroblast activation by transforming growth factor-beta-Implications for pathological extracellular matrix remodeling in heart valve disease. Circ Res 95:253-260.
65. Wang TN, Ge YK, Li JY, Zeng XH, Zheng XX. 2007. B-type natriuretic peptide enhances mild hypoxia-induced apoptotic cell death in cardiomyocytes. Biol Pharm Bull 30:1084-1090.
66. Weber KT, Brilla CG, Janicki JS. 1993. Myocardial fibrosis: Functional significance and regulatory factors. Cardiovasc Res 27:341-348.
67. Weiss JN, Korge P, Honda HM, Ping PP. 2003. Role of the mitochondrial permeability transition in myocardial disease. Circ Res 93:292-301.
68. Williams E, Iredale J. 2000. Hepatic regeneration and TGF-beta: Growing to a prosperous perfection. Gut 46:593-594.
69. Yan XM, Kim CH, Lee CK, Shin JS, Cho IH, Sohn UD. 2010. Intestinal absorption of fibrinolytic and proteolytic lumbrokinase extracted from earthworm, Eisenia andrei. Korean J Physiol Pharmacol 14:71-75.
70. Yu L, Noble NA, Border WA. 2002. Therapeutic strategies to halt renal fibrosis. Curr Opin Pharmacol 2:177-181.